Insight Molecular Diagnostics (IMDX) Depreciation & Amortization (CF) (2016 - 2026)
Insight Molecular Diagnostics' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $563000.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) fell 10.49% to $563000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 40.03% increase, with the full-year FY2025 number at $2.2 million, up 40.03% from a year prior.
- Depreciation & Amortization (CF) hit $563000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $584000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for IMDX hit a ceiling of $629000.0 in Q4 2024 and a floor of $121000.0 in Q1 2021.
- Historically, Depreciation & Amortization (CF) has averaged $379850.0 across 5 years, with a median of $387500.0 in 2022.
- Biggest five-year swings in Depreciation & Amortization (CF): surged 269.57% in 2021 and later tumbled 30.44% in 2024.
- Tracing IMDX's Depreciation & Amortization (CF) over 5 years: stood at $218000.0 in 2021, then soared by 83.49% to $400000.0 in 2022, then decreased by 27.0% to $292000.0 in 2023, then soared by 115.41% to $629000.0 in 2024, then dropped by 10.49% to $563000.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for IMDX at $563000.0 in Q4 2025, $584000.0 in Q3 2025, and $559000.0 in Q2 2025.